

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **RAPID DOSE THERAPEUTICS CORP.** (the "Issuer").

Trading Symbol: **DOSE**

Number of Outstanding Listed Securities: **75,121,327**

Date: **April 5, 2019**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer is a Canadian bio-technology company which provides proprietary enhanced drug delivery technologies designed to improve patient outcomes. The Issuer owns a proprietary oral fast-dissolving drug delivery system, QuickStrip™, which is capable of rapidly releasing into the blood stream a list of pharmaceuticals, emulsified oils and over-the-counter

medicines without being degraded or modified by first pass metabolism in the liver. The Issuer also provides product innovation, production and consultation to the pharmaceutical and healthcare manufacturing industry. The Issuer continues to execute on its strategy to enter the nutraceutical/over-the-counter sector initially through the completion of distribution agreements for the rights to sell nutraceuticals and over-the-counter products under the Issuer's brand name QuickStrip™ by distributors. The Issuer is sourcing distribution in other countries in order to take advantage of the production capabilities the Issuer has acquired through its nutraceutical co-packing supply agreement. The United States provides a significant second opportunity with its large complement of national retailers.

During the month the Issuer announced the completion of a vertical amalgamation with its wholly-owned subsidiary Rapid Dose Therapeutics Inc. The amalgamation did not require shareholder approval and was completed to simplify the corporate structure of the Issuer. No securities were issued in connection with the Amalgamation. The shares of the subsidiary were cancelled without any repayment of capital in respect of them.

During the month the Issuer was successful in obtaining a summary judgement against CTT Pharmaceutical Holdings, Inc. ("CTT") dismissing CTT's lawsuit against the Issuer.

The Issuer continued with its marketing strategy for nutraceuticals by outsourcing the production of certain selected natural healthcare product using its QuickStrip™ thin-film strips as a product delivery method.

The Issuer continues to negotiate and secure, on a selective basis, managed strip services ("MSS") agreements to license the QuickStrip™ technology to regulatory approved companies supplying cannabis products in their specified jurisdictions. The Issuer is party to five MSS agreements.

During the month the Issuer announced it had signed a Memorandum of Understanding ("MOU") with Thrive Cannabis ("Thrive") providing Thrive the rights to sell oral thin film strips with the Issuer's QuickStrip™ technology. A White Label Manufacturing ("WLM") Agreement is scheduled to close on or before April 15, 2019, subject to the approval of the Board of Directors of each company.

2. Provide a general overview and discussion of the activities of management.

In March, the Issuer's management assisted with the developments outlined in Section 1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

N/A

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

N/A

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

During the month the Issuer announced it had signed a MOU with Thrive providing Thrive the rights to sell oral thin film strips with the Issuer's QuickStrip™ technology. A WLM Agreement is scheduled to close on or before April 15, 2019, subject to the approval of the Board of Directors of each company..

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

N/A

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

N/A

8. Describe the acquisition of new customers or loss of customers.

See Numbers 1 and 5 above.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

N/A

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

N/A

11. Report on any labour disputes and resolutions of those disputes if applicable.

N/A

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal

parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

In connection with a Statement of Claim issued in the Ontario Superior Court of Justice by CTT and served on the Issuer on or about September 27, 2018, alleging that the Issuer used confidential information provided by CTT relating to oral thin film technology, breached obligations of confidence and interfered with CTT’s economic interests (the “CTT Claim”), during the month the Issuer was successful in obtaining a summary judgement against CTT Pharmaceutical Holdings, Inc. (“CTT”), dismissing CTT’s lawsuit against the Issuer.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

N/A

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Stock Options	4,526,000	4,526,000 stock options granted, exercisable at \$0.82 per share at any time on or before March 11, 2024.	N/A (Proceeds available only upon exercise – working capital upon exercise)

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons. **N/A**
16. Provide details of any changes in directors, officers or committee members.
N/A
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

The Issuer remains subject to general market trends that can impact its sector. The Issuer is exposed to risks of varying degrees of significance which could affect its ability to achieve its strategic objectives. Although the Issuer has completed initial sales in Canada and the United States, there is no assurance that the market for the Issuer’s QuickStrip™ natural healthcare products will grow into any substantial volumes or become profitable. The Issuer has no history of earnings.

The Issuer’s QuickStrip™ medical delivery device requires the approval of Health Canada under *The Access to Cannabis for Medical Purposes Regulations* (“ACMPR”) to enable the Issuer’s subsidiary’s Canadian Licensed Producer customers the right to sell cannabis oil as a QuickStrip™. There is no assurance, at this time, that an application by the Issuer’s

customers will result in an approval of the oral film strip as an allowable delivery device under present ACMPR regulations. Future amendments to the ACMPR governing the production and distribution of cannabis edibles in Canada will create an additional opportunity for the approval of the Quickstrip™ as an allowable delivery device. There is presently no fixed timeline as to when amendments to the ACMPR will occur. The Issuer believes the Quickstrip™ device has consumer benefits and the required scientific data supporting the process used by Health Canada for approving the oral thin film strip will be provided.

The Issuer's cannabis grower customers are subject to a variety of laws, regulations and guidelines relating to the manufacture of cannabis and cannabis-related products as well as laws and regulations relating to health and safety, the conduct of operation and the protection of the environment. Changes to such laws, regulations and guidelines due to matters beyond the control of the Issuer may cause adverse effects to the Issuer's Canadian operations with its Canadian licensed cannabis producer customers.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated **April 5, 2019**_____.

LINO FERA_____

Name of Director or Senior
Officer

Signed "Lino Fera"_____

Signature

**Chief Financial Officer and
Corporate Secretary**_____

Official Capacity

<i>Issuer Details</i>		
Name of Issuer RAPID DOSE THERAPEUTICS CORP.	For Month End March 31, 2019	Date of Report YY/MM/D 19 / 04 / 05
Issuer Address 1121 Walkers Line		
City/Province/Postal Code Burlington, Ontario	Issuer Fax No. (416) 361-1333	Issuer Telephone No. (416) 477-1052
Contact Name JORGE ESTEPA	Contact Position Assistant Corporate Secretary	Contact Telephone No. (416) 818-4035
Contact Email Address jestepa@rapid-dose.com	Web Site Address www.rapid-dose.com	